Jiamin Zhu

Jiamin Zhu

Auto-generated profile, based on publicly available information

Jiamin Zhu

Department of Oncology, Jiangyin Clinical College of Xuzhou Medical University, Jiangyin, China

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
16 April 2021 in Medicine
Verified
Journal Article
Open access
JZJiamin Zhu
Jiamin Zhu
XLXiao Liang
Xiao Liang
DWDan Wu
Dan Wu
SCShusen Chen
Shusen Chen
BYBaixia Yang
Baixia Yang
DSDong Shen
Dong Shen
Objective: This study aimed to investigate the clinicopathological features and the survival outcomes of neuroendocrine prostate cancer (NEPC). Methods: Within the Surveillance, Epidemiology, and End Results (SEER) database of the National Cancer Institute, we identified a total of 510 patients with NEPC between 2006 and 2015. Age-adjusted incidence rates were evaluated in the study by the SEER∗Stat Software version 8.3.6. Kaplan–Meier analysed assessed overall survival (OS) after stratification according to marital status, age, histologic subtype, metastatic status, and treatment. The significant differences were assessed in a log-rank test. Univariate and multivariate cox hazard regression analysis were performed to determine independent predictors of OS. Results: From a total of 560,124 patients with prostate cancer diagnosed between 2006 and 2015, we identified 510 cases of de novo NEPC. Regarding histology, among all the NEPC, 329 (64.5%) patients were diagnosed as small cell carcinoma, 181 (39.8%) were nonsmall cell carcinoma. The overall age-adjusted incidence of NEPC statistically significantly increased from 0.321/1,000,000 person-years in 2006 to 0.587/1,000,000 person-years in 2015. The median OS in our study cohort was 9 months (95% CI, 8–10 months). Multivariate cox regression analysis showed that age, histologic subtype, and stage were independent prognostic factors for NEPC patients. The majority of NEPC (78.2%) were metastatic at diagnosis. In terms of treatment, for metastatic tumor patients, chemotherapy was the most effective therapy. Chemotherapy increased the OS of patients with regional (distant) metastases from 8 months (5 months) to 13.5 months (9 months). Conclusion: NEPC is extremely rare but the incidence of NEPC has been increasing in the past years. The prognosis of NEPC is poor because most cases are diagnosed at metastatic stage. The patients with metastases are typically treated with chemotherapy and chemotherapy shows survival benefits in both regional and distant metastatic tumor patients.

12 March 2026 in Molecular Biomedicine
Verified
Journal Article
Open access
PDF file
JZJiamin Zhu
Jiamin Zhu
LLLiting Lv
Liting Lv
YYYuqian Yan
Yuqian Yan
SWSimin Wang
Simin Wang
XLXiangdong Lu
Xiangdong Lu
XLXiao Liang
Xiao Liang
Autophagy represents a conserved lysosome-dependent catabolic mechanism that safeguards cellular energetic homeostasis and supports adaptive metabolic remodeling under diverse stress conditions. In cancer, autophagy displays a highly context-dependent “double-edged sword” behavior. During the early stages of tumorigenesis, autophagy can suppress malignant transformation by preserving genomic stability, restraining chronic inflammation, and limiting the acquisition of malignant stemness, thereby helping preserve cellular integrity in early tumorigenesis. However, as tumors progress, autophagy can be reprogrammed into an adaptive survival mechanism that supplies tumor growth, metastatic dissemination, and resistance to multiple therapeutic modalities in response to hypoxia, nutrient deprivation, and therapeutic stress. Within the framework of tumor evolution, this review systematically integrates the molecular mechanisms and regulatory networks underlying different forms of autophagy, including canonical, non-canonical, and selective forms. We explore how autophagy intersects with metabolic reprogramming, immune signaling, DNA damage responses, and regulated cell death, and discuss its involvement in tumor progression, microenvironment remodeling, metastasis, and therapy resistance, with relevance to interactions between tumor cells and the surrounding microenvironment. We also summarize recent developments in autophagy-targeted approaches, including chloroquine derivatives, emerging small-molecule inhibitors, and natural compounds, and consider the challenges that remain for clinical translation, especially those related to context-dependent effects and therapeutic application. Collectively, this review provides an updated understanding of autophagy in tumor evolution and informs future mechanistic and therapeutic investigations.

11 January 2022 in Journal of Oncology
Verified
Journal Article
Open access
PDF file
JZJiamin Zhu
Jiamin Zhu
ZLZhili Liu
Zhili Liu
XLXiao Liang
Xiao Liang
LWLu Wang
Lu Wang
DWDan Wu
Dan Wu
DSDong Shen
Dong Shen
Objective. Exome sequencing studies have shown that the histone-lysine N-methyltransferase 2 (KMT2) gene is one of the most commonly mutated genes in a range of human malignancies and is linked to some of the most common and deadly solid tumors. However, the connection between this gene familys function and tumor type, immunological subtype, and molecular subtype dependency is still unknown. Methods. We examine the expression patterns of the histone-lysine N-methyltransferase 2 (KMT2) gene, as well as their relationship to patient survival. We also used a pan-cancer analysis to link their function to immunological subtypes, the tumor microenvironment, and treatment sensitivity. Results. Using the TCGA pan-cancer data, researchers looked at and examined KMT2 expression patterns and their links to patient survival and the tumor microenvironment in 33 cancer types. The expression of the KMT2 family changes significantly across and within cancer types, indicating significant inter- and intracancer heterogeneity. Patients overall survival was often linked to the expression of KMT2 family members. However, the direction of the link differed depending on the KMT2 isoform and cancer type studied. Notably, in all cancer types examined, nearly all KMT2 family members were substantially linked with overall survival in patients with renal clear cell carcinoma (KIRC). Furthermore, all KMT2 genes have a strong relationship with immune infiltrate subtypes, as well as varying degrees of stromal cell infiltration and tumor cell stemness. Finally, we discovered that higher expression of KMT2s, particularly KMT2F and KMT2G, was linked to greater chemotherapeutic sensitivity in several cell lines. Conclusions. The necessity to investigate each KMT2 member as a distinct entity inside each particular cancer type is highlighted by our comprehensive investigation of KMT2 gene expression and its relationship with immune infiltrates, tumor microenvironment, and cancer patient outcomes. Our research also confirmed the identification of KMT2 as a potential therapeutic target in cancer, but further laboratory testing is required.

10 November 2023 in Heliyon
Verified
Journal Article
Open access
JZJiamin Zhu
Jiamin Zhu
XLXiao Liang
Xiao Liang
SCShusen Chen
Shusen Chen
YQYa Qin
Ya Qin
DSDong Shen
Dong Shen
XYXi Yang
Xi Yang
Endoscopic therapy is an optional strategy for the treatment of esophageal cancer (EC) under an early stage, especially stage T1a. However, its efficacy in the treatment of T1b EC has not been thoroughly assessed. We investigated the efficacy of esophagectomy, endoscopic therapy, as well as chemoradiotherapy in patients with T1bN0M0 EC. The Surveillance, Epidemiology, and End Results database (SEER) was employed to identify patients diagnosed with T1bN0M0 EC. Patient demographics were compared among the endoscopic therapy, esophagectomy, and chemoradiotherapy groups. Our study employed Kaplan-Meier analysis and Cox regression model to evaluate patient outcomes and long-term survival rates. The overall survival (OS) and cancer-specific survival (CSS) rates were compared among patients with EC who underwent endoscopic therapy or esophagectomy, employing propensity score matching (PSM). A total of 820 patients diagnosed with T1bN0M0 EC were identified. The number of patients who received endoscopic therapy, esophagectomy, and chemoradiotherapy was 173, 556, and 91, respectively. Patients subjected to endoscopic therapy and esophagectomy had greatly longer OS and CSS than those who underwent chemoradiotherapy. Patients treated with esophagectomy had longer OS than endoscopic therapy patients, but there were no differences in CSS between the two groups. PSM generated 153 patient pairs among T1bN0M0 patients, demonstrating that both the esophagectomy and endoscopic therapy groups exhibited comparable OS and CSS rates. Endoscopic therapy and esophagectomy were associated with a significant survival advantage compared with chemoradiotherapy in patients with T1bN0M0 EC. In contrast, after PSM, among the EC patients with stage T1bN0M0, OS and CSS did not differ after endoscopic therapy or esophagectomy. These results indicate that endoscopic therapy could be a viable alternative to esophagectomy in patients diagnosed with T1bN0M0 EC.